Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands

Name: Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands
SKU: 4129
Price: 30.00 USD
Availability: InStock

$30.00

ORIGINAL RESEARCH

Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands

By Anton B.P. Staring, C.L. Mulder, S. Priebe

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 43 No. 1 Articles Tags: anton-b-p-staring, c-l-mulder, original-research, s-priebe, schizophrenia, schizophrenia-adherence-medication-antipsychotic-medication, the-netherlands

Description

Description

ORIGINAL RESEARCH

Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands

By Anton B.P. Staring, C.L. Mulder, S. Priebe

PB-43-1-2010_STARRING

Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands

Description

Risperidone: Review of Its Therapeutic Utility in Depression

Neuropsychiatric Update: Neuroimaging Schizophrenia

Mikael Landén, MD, PhD: Treatment Refractory Psychosis Remitted Upon Treatment with Continuous Positive Airway Pressure: A Case Report

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands

Description

Related products

Risperidone: Review of Its Therapeutic Utility in Depression

Neuropsychiatric Update: Neuroimaging Schizophrenia

Mikael Landén, MD, PhD: Treatment Refractory Psychosis Remitted Upon Treatment with Continuous Positive Airway Pressure: A Case Report

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia